Year: 2015

ER Stress Sensor XBP1 as a Key Regulator of Ovarian Cancer Immunity

While T cell-based therapies represent a novel approach to complement current treatments for metastatic ovarian cancer, tumor-induced immunosuppression restrains the optimal activity of cancer-reactive T cells…

Read on

Novel Extra Cellular RNA-based Combinatorial RNA Inhibition Therapy

Serous ovarian cancer remains the leading cause of death among gynecologic malignancies. This is due to high rates of disease recurrence (>70%) after the standard therapy, highlighting the crucial need to develop better therapeutic strategies…

Read on

Long Non-coding RNAs in Epithelia Ovarian Cancer

The human genome is made up of all the deoxyribonucleic acid (DNA) contained in our cells. Our DNA is made up of six billion individual DNA “letters” which are packaged into chromosomes…

Read on

Microenvironmental Control of Premalignant Lesions in Ovarian Cancer

Ovarian cancer is a number one killer of all women’s malignancies, however mechanisms of its development from a pre-cancerous lesion are still poorly understood. In this study, Dr…

Read on

Cancer-prone Stem Cell Niches in Ovarian and Tubal Epithelia

Ovarian cancer is the most lethal gynecological malignancy and is the 5th most frequent cause of cancer-related deaths among women in the US. Nearly 70% of women are diagnosed with advanced, incurable stages of the disease…

Read on

Using Functional Genetics and Nanomedicine for Ovarian Cancer Treatments

Ovarian cancer is the fifth deadliest cancer among women in the United States. In spite of advances in surgery and drug therapy over the past several decades, cure rates remain very low (~30%)…

Read on

EMSY Suppresses HDR in a BRCA2-interaction-independent Manner

Ongoing efforts in our laboratory have been towards understanding the biology of ovarian cancer and identifying new treatments from which patients with ovarian cancer could benefit…

Read on

Synthetic Lethality Between CCNE1 Amplification and USP1 Inhibition

High grade serous ovarian cancer (HGSC) accounts for more than 60% of the ovarian cancer deaths and almost no improvement in survival rates has been observed in the past decade…

Read on

Combination Oncolytic Virotherapy/ACT for Ovarian Cancer Treatment

Researchers are currently investigating novel cancer treatments that act to instruct the immune system to efficiently seek out and destroy tumor cells in the body, known collectively as cancer immunotherapies…

Read on

Targeting FSH Receptor with Chimeric Antigen Receptor in Ovarian Cancer

Ovarian cancer is one of the most deadly tumors, killing ~15,000 women each year in the US. Despite advances in its treatment, survival of women with this disease has not improved in the last 40 years…

Read on

Identification of New Genetic Dependencies in HR-deficient Ovarian Cancers

Our DNA is constantly exposed to damage due to environmental insults and normal cellular processes…

Read on

Genomic Analysis to Predict Recurrence in Early Stage Ovarian Cancer

The survival of women with high-grade epithelial ovarian cancer is directly related to the spread of the tumor…

Read on